RT Journal Article
T1 Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.
A1 Rodriguez-Gil, Alfonso
A1 Escamilla-Gomez, Virginia
A1 Nufer, Melanie
A1 Andujar-Sanchez, Felix
A1 Lopes-Ramos, Teresa
A1 Bejarano-Garcia, Jose Antonio
A1 Garcia-Guerrero, Estefania
A1 Calderon-Cabrera, Cristina
A1 Caballero-Velazquez, Teresa
A1 Garcia-Calderon, Clara Beatriz
A1 Hernandez-Diaz, Paola
A1 Reguera-Ortega, Juan Luis
A1 Rodriguez-Torres, Nancy
A1 Martinez-Cibrian, Nuria
A1 Rodriguez-Barbosa, Jose Ignacio
A1 Villadiego, Javier
A1 Perez-Simon, Jose Antonio
K1 Bone marrow transplantation
K1 Haematological cancer
AB Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.
PB Nature Publishing Group
YR 2022
FD 2022-05-19
LK http://hdl.handle.net/10668/19610
UL http://hdl.handle.net/10668/19610
LA en
NO Rodríguez-Gil A, Escamilla-Gómez V, Nufer M, Andújar-Sánchez F, Lopes-Ramos T, Bejarano-García JA, et al.  Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib. Sci Rep. 2022 May 19;12(1):1-13.
DS RISalud
RD Apr 17, 2025